logo
Plus   Neg
Share
Email

AstraZeneca: Roxadustat Phase III Pooled Analyses Show Positive Efficacy

AstraZeneca plc (AZN.L,AZN) and FibroGen Inc. have reported pooled efficacy and cardiovascular safety analyses from the Phase III programme assessing roxadustat for the treatment of patients with anaemia from chronic kidney disease. The company said the results demonstrated the potential of roxadustat to address significant unmet medical needs among patients with anaemia from chronic kidney disease, particularly for those who have recently started dialysis.

The primary efficacy endpoint was achieved in the pooled analyses for non dialysis-dependent and dialysis-dependent patients, and in all individual Phase III trials. The study data will form part of the regulatory submission in the US, which is anticipated in the fourth quarter of 2019.

Mene Pangalos, Executive Vice President, BioPharmaceuticals, R&D, said: "The pooled analyses showed incident dialysis patients receiving roxadustat had a lower risk of cardiovascular events which is important as these patients may experience higher rates of morbidity and mortality than those on stable dialysis."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Airbnb has introduced few new rules to control parties and nuisances amidst the backlash the service received after the Halloween shooting at an Airbnb rental in a San Francisco. San Francisco-based Airbnb said it is banning "open invite" parties at all of its accommodations. The company is also banning... The U.S. Food and Drug Administration has approved three generic versions of Novartis' Gilenya capsule for treating relapsing forms of multiple sclerosis. "Approving safe and effective generics so patients have more treatment options continues to be a priority for the FDA," said Janet Woodcock, director... Shares of Upscale furniture chain RH (RH) are on a tear, on the heels of an upbeat annual forecast. Today, the stock set a new all-time high of $239.88.The stock is up more than 20% from its Dec 3 opening price of $196.66, and currently trading at $237.8, and nearly three-times its 52-week low of $84.11....
Follow RTT
>